Pbs Newshour - Making Sen$e

COVID-19 vaccine development continues to be the subject of political jostling, with President Trump contradicting top U.S. health officials regarding timeline and efficacy. The Centers for Disease Control and Prevention say they expect to distribute vaccines publicly at no cost to the patient. But what will the government pay, and how much could drug companies profit? Paul Solman reports. PBS NewsHour is supported by - https://www.pbs.org/newshour/about/funders

U.S. airlines are sending out warnings about huge financial losses and urgently requesting help. Tens of thousands of flights for the fall have been canceled, and change fees have been eliminated in order to attract travelers. Meanwhile, flight staff and security are being drawn into arguments with passengers who refuse to comply with mask mandates. Economics correspondent Paul Solman reports. PBS NewsHour is supported by - https://www.pbs.org/newshour/about/funders

Throughout the Republican National Convention, supporters of President Trump have touted his economic record as a key reason they believe he should be reelected. But what would a second-term policy agenda look like for Trump, as the coronavirus pandemic continues to limit economic growth and threaten American jobs? Paul Solman reports on Trump's record so far and proposals for the future. PBS NewsHour is supported by - https://www.pbs.org/newshour/about/funders

With tens of millions of Americans reeling financially from the coronavirus pandemic, the future of the U.S. economy is on the minds of many. Both President Trump and Democratic challenger Joe Biden are seeking to convince voters they can revive the country. But what do their respective policies suggest? Paul Solman analyzes some of Biden's key economic proposals -- and how he would pay for them. PBS NewsHour is supported by - https://www.pbs.org/newshour/about/funders

The antibiotics industry has suffered an alarming collapse that has become even more troubling as secondary bacterial infections threaten patients with COVID-19. Why has production of these vital medicines stagnated, and what can be done to address the problem? Economics correspondent Paul Solman reports on why lifesaving drugs don't necessarily translate to lucrative businesses. PBS NewsHour is supported by - https://www.pbs.org/newshour/about/funders